CGEN.TA - Compugen Ltd.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
1,261.00
+85.00 (+7.23%)
As of 2:55PM IDT. Market open.
Stock chart is not supported by your current browser
Previous Close1,176.00
Open1,260.00
Bid1,261.00 x 1500
Ask1,264.00 x 200
Day's Range1,254.00 - 1,262.00
52 Week Range823.00 - 1,636.00
Volume34,789
Avg. Volume23,194
Market Cap687.71M
Beta0.27
PE Ratio (TTM)N/A
EPS (TTM)-0.55
Earnings DateMay 7, 2018 - May 11, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Thomson Reuters StreetEvents7 days ago

    Edited Transcript of CGEN.TA earnings conference call or presentation 1-Aug-18 12:30pm GMT

    Q2 2018 Compugen Ltd Earnings Call

  • Associated Press18 days ago

    Compugen: 2Q Earnings Snapshot

    The Holon, Israel-based company said it had a loss of 19 cents per share. The company's shares closed at $3.15. A year ago, they were trading at $4.05. _____ This story was generated by Automated Insights ...

  • PR Newswire18 days ago

    Compugen Reports Second Quarter 2018 Results

    Preparations for first patient dosing on track to take place in early fall HOLON, ISRAEL , Aug 1, 2018 /PRNewswire/ -- Compugen Ltd. ( Nasdaq: CGEN ), a clinical-stage cancer immunotherapy company and ...

  • PR Newswirelast month

    Compugen Second Quarter 2018 Conference Call Scheduled for Wednesday, August 1, 2018 at 8:30 AM ET

    HOLON, Israel , July 18, 2018 /PRNewswire/ --  Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company ...

  • Benzinga2 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Alkermes Plc (NASDAQ: ALKS ) stock was trading higher ...

  • PR Newswire2 months ago

    Compugen Welcomes FDA Clearance of Bayer's IND Application for BAY 1905254

    HOLON, Israel, July 2, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN) (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, was informed that the U.S. Food and Drug Administration (FDA) has cleared Bayer AG's investigational new drug (IND) application for BAY 1905254, a first-in-class immuno-oncology therapeutic antibody targeting the ILDR2 protein in patients with advanced solid tumors. ILDR2 is a novel immune checkpoint discovered by Compugen through its predictive computational capabilities, which enable the discovery of new drug targets and biological pathways.

  • When Should You Buy Compugen Ltd (NASDAQ:CGEN)?
    Simply Wall St.2 months ago

    When Should You Buy Compugen Ltd (NASDAQ:CGEN)?

    Compugen Ltd (NASDAQ:CGEN), a life sciences company based in Israel, saw a double-digit share price rise of over 10% in the past couple of months on the NasdaqGM. Less-covered, smallRead More...

  • PR Newswire2 months ago

    Compugen Announces the Appointment of New Board Members

    HOLON, Israel, June 11, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the appointment of three new members to its Board of Directors. Mr. Gilead Halevy, founding member and general partner of Kedma Capital Partners, Kinneret Livnat Savitzky, Ph.D., Interim CEO and board member of FutuRx Ltd., and Mr. Sanford (Sandy) Zweifach, founder and CEO of Nuvelution Pharma, Inc. were appointed to Compugen's Board.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of CGEN.TA earnings conference call or presentation 9-May-18 1:45pm GMT

    Q1 2018 Compugen Ltd Earnings Call

  • Market Has Not Yet Noticed Potential in Compugen; Have You?
    Zacks3 months ago

    Market Has Not Yet Noticed Potential in Compugen; Have You?

    Compugen (CGEN) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.

  • Associated Press3 months ago

    Compugen: 1Q Earnings Snapshot

    On a per-share basis, the Holon, Israel-based company said it had profit of less than 1 cent. The drug developer posted revenue of $10 million in the period. The company's shares closed at $3.33. A year ...

  • PR Newswire3 months ago

    Compugen Reports First Quarter 2018 Results

    HOLON, Israel , May 9, 2018 /PRNewswire/ --  Compugen Ltd.  (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for ...

  • Compugen Ltd (NASDAQ:CGEN): Should The Recent Earnings Drop Worry You?
    Simply Wall St.4 months ago

    Compugen Ltd (NASDAQ:CGEN): Should The Recent Earnings Drop Worry You?

    When Compugen Ltd (NASDAQ:CGEN) released its most recent earnings update (31 December 2017), I wanted to understand how these figures stacked up against its past performance. The two benchmarks IRead More...

  • PR Newswire4 months ago

    Preclinical Data Presented by Bayer at AACR Highlights BAY 1905254, Formerly the CGEN-15001T Program, Efficacy in Cancer Immunotherapy

    HOLON, Israel, April 17, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that preclinical data presented by Bayer AG at the Annual Meeting of the American Association of Cancer Research held April 14-18, 2018, in Chicago, Illinois, highlights the efficacy of BAY 1905254 (formerly the CGEN-15001T program) in cancer immunotherapy. BAY 1905254 is a first-in-class therapeutic antibody candidate targeting ILDR2, a novel immune checkpoint discovered by Compugen.

  • Reuters5 months ago

    UK Stocks-Factors to watch on April 3

    (Adds company news items and futures) April 3 (Reuters) - Britain's FTSE 100 index is seen opening 46 points lower at 7,011 on Tuesday, according to financial bookmakers, with futures down 1.15 percent ...

  • Reuters5 months ago

    Deals of the day-Mergers and acquisitions

    (Adds Elliott, COFCO Property, ReNew Power, General Electric; Updates Transcontinental) April 2 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday: ...

  • Benzinga5 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! SYNNEX Corporation (NYSE: SNX ) stock lost more than ...

  • Reuters5 months ago

    Compugen, AstraZeneca unit in cancer drug development deal

    Israeli drugmaker Compugen Ltd (CGEN.TA) (CGEN.O) said it had agreed an exclusive licensing deal with a unit of AstraZeneca (AZN.L) to develop antibody products to treat cancer, which could be worth more than $200 million (142.25 million pounds). Under the terms of the deal announced on Monday, MedImmune - the research and development arm of AstraZeneca - will develop genetically engineered antibody products derived from Compugen's oncology drug pipeline and pay royalties to the Israeli firm.

  • Reuters5 months ago

    Compugen, AstraZeneca unit in cancer drug development deal

    Israeli drugmaker Compugen Ltd said it had agreed an exclusive licensing deal with a unit of AstraZeneca to develop antibody products to treat cancer, which could be worth more than $200 million. Under the terms of the deal announced on Monday, MedImmune - the research and development arm of AstraZeneca - will develop genetically engineered antibody products derived from Compugen's oncology drug pipeline and pay royalties to the Israeli firm.

  • At $3.95, Is Compugen Ltd (NASDAQ:CGEN) A Buy?
    Simply Wall St.5 months ago

    At $3.95, Is Compugen Ltd (NASDAQ:CGEN) A Buy?

    Compugen Ltd (NASDAQ:CGEN), a life sciences company based in Israel, led the NasdaqGM gainers with a relatively large price hike in the past couple of weeks. Less-covered, small caps tendRead More...

  • PR Newswire5 months ago

    Compugen Announces Appointment of Henry Adewoye, MD, as Chief Medical Officer

    HOLON, Israel, March 26, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced the appointment of Dr. Henry Adewoye, to the newly created position of Chief Medical Officer, effective immediately. Dr. Adewoye brings to Compugen over two decades of extensive and broad experience in leading multiple clinical trials in oncology and hematology in both the biopharmaceutical industry and academia.  As Chief Medical Officer, Dr. Adewoye will play a key role in leading the Company's transition into a clinical stage company, and will assume overall responsibility of Compugen's clinical stage pipeline programs.

  • Simply Wall St.5 months ago

    Compugen Ltd (NASDAQ:CGEN): Should The Future Outlook Worry You?

    Compugen Ltd’s (NASDAQ:CGEN) most recent earnings announcement in December 2017 suggested company earnings became less negative compared to the previous year’s level as a result of recent tailwinds Today IRead More...

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of CGEN.TA earnings conference call or presentation 21-Feb-18 3:00pm GMT

    Q4 2017 Compugen Ltd Earnings Call

  • Associated Press6 months ago

    Compugen reports 4Q loss

    The Holon, Israel-based company said it had a loss of 18 cents per share. For the year, the company reported that its loss widened to $37.1 million, or 72 cents per share. The company's shares closed at ...